Webb14 okt. 2024 · Conclusion The SHARP-ER study will contribute important evidence on the long-term outcomes of cholesterol-lowering therapy in patients with advanced CKD with a total of 10 years of follow-up.... WebbThe key question in the SHARP trial was does lipid lowering therapy in chronic kidney disease (CKD) reduce the risk of atherosclerotic and vascular events and there is no …
Rosuvastatin and Cardiovascular Events in Patients …
WebbChronic kidney disease (CKD) is one of the most important risk factors for cardiovascular disease (CVD). Despite the kidney having no direct implications for lipoproteins metabolism, advanced CKD dyslipidemia is usually present in patients with CKD, and the frequent lipid and lipoprotein alterations occurring in these patients play a role of primary … Webb11 mars 2024 · The SHARP trial showed that lowering LDL cholesterol with a combination of simvastatin 20 mg plus ezetimibe 10 mg daily for about 5 years safely reduced the risk of major atherosclerotic events (i.e., nonfatal myocardial infarction or coronary death, nonhemorrhagic stroke, or arterial revascularization procedure) in nondialysis patients … brvnara cena
Lipid Management Guidelines for Adults with Chronic Kidney …
WebbObjective: To examine the long-term effects of lipid-lowering therapy on all-cause mortality, cardiovascular morbidity, CKD progression, and socioeconomic well-being in Australian, … WebbAim: To describe baseline medication use in CKD patients of the SHARP-ER study. Background: Medication use of patients with CKD in Australia is accepted as high, but systematic, national data has not been available. The Pharmaceutical Benefits Scheme (PBS) offers a novel means of real-world assessments medication use patterns in CKD. WebbAlthough the chief aim of SHARP is to determine any vascular benefits of LDL lowering among patients with advanced CKD, the trial also provides an opportunity to test the … brvnara krstigora